ESR1 and breast carcinoma: Using chromatin accessibility analysis, we investigated the epigenetic landscape in 23 breast cancer cell lines, including 2 ER+/HER2−, 3 ER+/HER2+, 3 HER2+, and 15 TNBC lines (Supplementary Table 1).